Experts and industry groups said newly implemented pharmaceutical tariffs—up to 100% on patented drugs and inputs—are adding cost and compliance uncertainty for small and mid-sized biotech firms. The lack of clear implementation guidance is complicating day-to-day planning and may reduce patient access by discouraging investment and development. The analysis cites Biotechnology Innovation Organization (BIO) data suggesting smaller biotechs drive much of industry output and new applications, making them particularly vulnerable to shocks like sudden tariff changes. Biotech operators are likely to face new operational constraints around manufacturing outsourcing, reporting burdens, and exemption pathways, with ripple effects for supply chain design and US capacity expansion decisions.